WO2013036282A3 - Downregulation of inflammatory micrornas by ilt3 - Google Patents
Downregulation of inflammatory micrornas by ilt3 Download PDFInfo
- Publication number
- WO2013036282A3 WO2013036282A3 PCT/US2012/024771 US2012024771W WO2013036282A3 WO 2013036282 A3 WO2013036282 A3 WO 2013036282A3 US 2012024771 W US2012024771 W US 2012024771W WO 2013036282 A3 WO2013036282 A3 WO 2013036282A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mirs
- discovered
- ilt3
- downregulation
- providing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
It has been discovered that inhibition of two or more specific inflammatory miRs (30b, 21, 146a, and 155) suppresses T cell proliferation, promotes T cell anergy or induces the formation of suppressor T cells, thereby providing a focused therapy with minimal toxicity for disorders associated with abnormally high immune responses. The corollary involves increasing the level of certain proinflammatory miRs thereby providing methods for immuno stimulation. It has also been discovered that significant increases of serum miR21 which occur in heart allograft rejection can be used to identify patients that have this disorder without requiring a biopsy.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161532031P | 2011-09-07 | 2011-09-07 | |
US61/532,031 | 2011-09-07 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2013036282A2 WO2013036282A2 (en) | 2013-03-14 |
WO2013036282A3 true WO2013036282A3 (en) | 2014-04-24 |
Family
ID=47832746
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2012/024771 WO2013036282A2 (en) | 2011-09-07 | 2012-02-10 | Downregulation of inflammatory micrornas by ilt3 |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2013036282A2 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006033811A2 (en) | 2004-09-03 | 2006-03-30 | The Trustees Of Columbia University In The City Of New York | Ilt3 polypeptides and uses thereof |
US9696312B2 (en) | 2011-09-02 | 2017-07-04 | The Trustees Of Columbia University In The City Of New York | Diagnosis and treatment of cancer expressing ILT3 or ILT3 ligand |
CN103571955A (en) * | 2013-10-28 | 2014-02-12 | 深圳市第二人民医院 | Application of DUSP-9 (dual-specificity phosphatase-9) gene to detection of renal clear cell carcinoma |
WO2015074083A1 (en) * | 2013-11-18 | 2015-05-21 | The Trustees Of Columbia University In The City Of New York | Methods for diagnosing t cell-mediated inflammation |
US20170130267A1 (en) * | 2014-03-17 | 2017-05-11 | Inserm (Institut National De La Sante Et De La Recerrche Medicale) | Methods for predicting acute rejection in heart recipients |
WO2015157678A2 (en) | 2014-04-10 | 2015-10-15 | The Trustees Of The University Of Pennsylvania | Use of micro-ribonucleic acid (mirna) to diagnose transplant rejection and tolerance of immunosuppression therapy |
CN105087477A (en) * | 2015-05-21 | 2015-11-25 | 王松灵 | Application of mesenchymal stem cell modified by miR-21 antisense nucleotide |
EP3325006A4 (en) | 2015-07-17 | 2019-03-06 | The Trustees of Columbia University in the City of New York | Methods of treating cd166-expressing cancer |
TW202428604A (en) | 2018-07-09 | 2024-07-16 | 美商戊瑞治療有限公司 | Antibodies binding to ilt4 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009100955A1 (en) * | 2008-02-14 | 2009-08-20 | Istituto Superiore di Sanità | Antisense rna targeting cxcr4 |
US20100086928A1 (en) * | 2006-12-20 | 2010-04-08 | The Brigham And Women's Hospital, Inc. | Detection of organ rejection |
US20100202973A1 (en) * | 2007-05-18 | 2010-08-12 | Karolinska Institutet Innovations Ab | Microrna molecules associated with inflammatory skin disorders |
WO2010130351A1 (en) * | 2009-05-15 | 2010-11-18 | Bayer Schering Pharma Ag | Micrornas as biomarkers and therapeutic targets for heart failure |
-
2012
- 2012-02-10 WO PCT/US2012/024771 patent/WO2013036282A2/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100086928A1 (en) * | 2006-12-20 | 2010-04-08 | The Brigham And Women's Hospital, Inc. | Detection of organ rejection |
US20100202973A1 (en) * | 2007-05-18 | 2010-08-12 | Karolinska Institutet Innovations Ab | Microrna molecules associated with inflammatory skin disorders |
WO2009100955A1 (en) * | 2008-02-14 | 2009-08-20 | Istituto Superiore di Sanità | Antisense rna targeting cxcr4 |
WO2010130351A1 (en) * | 2009-05-15 | 2010-11-18 | Bayer Schering Pharma Ag | Micrornas as biomarkers and therapeutic targets for heart failure |
Non-Patent Citations (1)
Title |
---|
PHAM ET AL.: "Essentials of Genomic and Personalized Medicine.", CLINICAL CARDIOLOGY (PHAM), 2010, pages 328 - 334, Retrieved from the Internet <URL:http://books.google.com/books?id=EIBwJ2ISRrACBpg=PA33281pg=PA3328dq=%222R/3A%22+rejection&source=bl&ots=fxhiOVcMXB&sig=W6gkktaDByqzOAbur7GyjqDias8&hl=en&sa=X&ei=J2GhT4-tM6PW2gWKq_DFCO&sqi=28ved=OCCgQ6AEwAQ#v=snippet&q=%222R%2F3A%22%208f=false> [retrieved on 20120502] * |
Also Published As
Publication number | Publication date |
---|---|
WO2013036282A2 (en) | 2013-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2013036282A3 (en) | Downregulation of inflammatory micrornas by ilt3 | |
MX2023001226A (en) | Anti-LAG-3 Antibodies. | |
MX2013014210A (en) | Antibodies specific for tgf-beta. | |
MX2016013963A (en) | Improved methods for manufacturing adoptive cell therapies. | |
PH12016500783A1 (en) | Suspension and clustering of human pluripotent stem cells for differentation into pancreatic endocrine cells | |
WO2013124817A3 (en) | MicroRNAS FOR THE GENERATION OF ASTROCYTES | |
WO2014028493A3 (en) | Exosomes and micro-ribonucleic acids for tissue regeneration | |
MX2015000428A (en) | Compositions and methods for regulating car t cells. | |
WO2012056457A3 (en) | Compositions and methods for activating expression by a specific endogenous mirna | |
WO2012149546A3 (en) | Small molecule trail gene induction by normal and tumor cells as an anticancer therapy | |
EP2552483A4 (en) | Antibody-based depletion of antigen-presenting cells and dendritic cells | |
MX355606B (en) | Methods for diagnosing and treating eye-length related disorders. | |
EP2555627A4 (en) | Methods of treating cancer | |
PH12015501282B1 (en) | Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms | |
WO2008052740A3 (en) | Method for stimulating dendritic cells and cell product thus obtained for the autologous immunotherapy of solid human tumours | |
WO2013109055A3 (en) | Canine-derived natural killer cells, and mass proliferation method thereof | |
MX2013011421A (en) | Pyrazolo pyrimidine derivatives. | |
WO2015120436A3 (en) | Stat3 phosphorylation during graft-versus-host disease | |
MX2014000186A (en) | An antibody inducing antigen-specific t cell tolerance and use thereof. | |
GR1008177B (en) | Method for the treatment of fir-based extract exhibiting biological action - use of same for the cure of human and animal diseases | |
WO2013093512A3 (en) | Vaccine - screening method | |
MX2013012551A (en) | Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease. | |
WO2012136351A8 (en) | Tapentadol for treating pain associated with trigeminal neuralgia | |
WO2016037123A3 (en) | Compositions and methods for treating b cell mediated autoimmune disorders | |
朱慧 | A Brief Analysis of the Female Images in The Waste Land |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12830237 Country of ref document: EP Kind code of ref document: A2 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 12830237 Country of ref document: EP Kind code of ref document: A2 |